Ocugen (NASDAQ:OCGN – Free Report) had its price target raised by Chardan Capital from $4.00 to $5.00 in a research report sent to investors on Monday, Benzinga reports. Chardan Capital currently has a buy rating on the stock.
Separately, HC Wainwright reiterated a buy rating and issued a $7.00 price target on shares of Ocugen in a research report on Wednesday, April 3rd.
Read Our Latest Analysis on OCGN
Ocugen Stock Down 6.1 %
Institutional Trading of Ocugen
A hedge fund recently bought a new stake in Ocugen stock. David J Yvars Group bought a new position in shares of Ocugen, Inc. (NASDAQ:OCGN – Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 21,170 shares of the company’s stock, valued at approximately $35,000. Hedge funds and other institutional investors own 10.27% of the company’s stock.
About Ocugen
Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD.
Recommended Stories
- Five stocks we like better than Ocugen
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- It’s Time to Buy Into the Super Micro Computer Stock Implosion
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Merger or Not, Albertson’s Companies is a Good Buy
- What Are Dividend Achievers? An Introduction
- 3 Cheap Stocks That Shouldn’t Be So
Receive News & Ratings for Ocugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocugen and related companies with MarketBeat.com's FREE daily email newsletter.